SEC filings
Boston Scientific (BSX)
Recent filings Boston Scientific made with the SEC, newest first. Most have a short AI-generated summary, and every one links to the original.
CIK 0000885725All filings on SEC.gov
10-QQuarterly report
Quarterly report
Boston Scientific reported third-quarter 2026 net sales of $5.138 billion, up 1.5%, and net income attributable to common stockholders of $582 million, down 22.9%, after an August 2026 cybersecurity incident disrupted manufacturing and…
8-KCurrent report
Results of Operations and Financial Condition
Boston Scientific reported third-quarter 2026 net sales of $5.138 billion, up 1.5% from a year earlier, with GAAP EPS of $0.40 and adjusted EPS of $0.73, and guided to full-year adjusted EPS of $3.16–$3.18 and a fourth-quarter net sales…
8-KCurrent report
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Other Events
Boston Scientific announced that Joseph M. Fitzgerald will become executive vice president and chief operating officer on Jan. 1, 2027, and that the company will establish three reportable segments—Interventional Therapies, Rhythm…
8-KCurrent report
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Arthur C. Butcher has informed Boston Scientific that he will retire as Executive Vice President and Group President, MedSurg and Asia Pacific effective January 1, 2027, and is expected to serve as a senior advisor through February 26…
8-KCurrent report
Material Cybersecurity Incidents
Boston Scientific said a cybersecurity incident identified on August 25, 2026 disrupted its IT systems and global operations, interrupting manufacturing and order processing, and that the incident is likely to materially affect…
8-KCurrent report
Other Events
Boston Scientific identified a cybersecurity incident on August 25, 2026 affecting certain of its information technology systems that has caused a global disruption to its operations, including limiting its ability to process and ship…
10-QQuarterly report
Quarterly report
Boston Scientific reported second-quarter 2026 net sales of $5.442 billion, up 7.5% from a year earlier, and net income attributable to common stockholders of $907 million, up 13.8%. …
8-KCurrent report
Results of Operations and Financial Condition
Boston Scientific reported second-quarter 2026 net sales of $5.442 billion, up 7.5% on a reported basis and 7.0% operationally and organically, with GAAP earnings of $0.61 per share and adjusted EPS of $0.86. …
8-KCurrent report
Costs Associated with Exit or Disposal Activities
Boston Scientific's board approved a 2026 global restructuring program on July 21, 2026, intended to drive cost efficiencies through supply chain optimization and organizational changes. …
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.
Follow Boston Scientific in Readster
Add Boston Scientific to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.
No credit card. When the trial ends, you move to Readster Free unless you subscribe.